Faruqi & Faruqi Investigates Claims for Investors in Aquestive Therapeutics
Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into the claims related to Aquestive Therapeutics, Inc. The law firm, known for its rigorous advocacy on behalf of investors, is looking into this matter following a troubling development for Aquestive Therapeutics.
On February 13, 2026, the firm's partner, James (Josh) Wilson, invited investors who may have suffered substantial losses in their investments in Aquestive Therapeutics to reach out for a discussion on potential legal avenues. This call to action is particularly pertinent given recent events where shares of Aquestive Therapeutics experienced an alarming decline of approximately 40% in intraday trading. This drastic drop followed an announcement from the U.S. Food and Drug Administration (FDA), which flagged deficiencies in the company's New Drug Application (NDA) concerning Anaphylm, their experimental treatment for severe allergic reactions, including anaphylaxis.
The FDA's identification of these deficiencies has raised significant concerns. It is known that such issues can greatly hinder the progress of drug approvals, as they obstruct discussions about essential labeling and post-marketing requirements. Thus, with the PDUFA action date slated for January 31, 2026, the specter of an approval delay looms large over Aquestive's future.
In light of these developments, Faruqi & Faruqi is urging shareholders of Aquestive Therapeutics, especially those who have incurred significant losses, to consider their legal options vigorously. Since its establishment in 1995, Faruqi & Faruqi has successfully recovered hundreds of millions of dollars for numerous investors, making it a powerhouse in securities litigation.
Investors are encouraged to evaluate their standing in relation to Aquestive Therapeutics and can find more information about the investigation on the firm’s dedicated webpage. Those wishing to discuss their situation directly can contact senior partner Josh Wilson either by phone or through their official website, www.faruqilaw.com/AQST.
Faruqi & Faruqi operates multiple offices across major locations including New York, Pennsylvania, California, and Georgia, which allows them to serve a diverse clientele effectively. The firm's reputation is founded not only on their legal prowess but also on the emphasis they place on confidentiality and individual client attention.
The situation regarding Aquestive Therapeutics is a reminder of the volatile nature of the pharmaceutical sector, especially concerning approvals from regulatory bodies like the FDA. Stakeholders in the healthcare industry are reminded of the importance of staying informed about their investments, particularly those that hinge significantly on regulatory milestones.
As the investigation unfolds, updates will be shared via platforms like LinkedIn, X, and Facebook, allowing concerned investors to stay abreast of any new developments regarding Aquestive Therapeutics and potential claims that may arise.
On February 13, 2026, the firm's partner, James (Josh) Wilson, invited investors who may have suffered substantial losses in their investments in Aquestive Therapeutics to reach out for a discussion on potential legal avenues. This call to action is particularly pertinent given recent events where shares of Aquestive Therapeutics experienced an alarming decline of approximately 40% in intraday trading. This drastic drop followed an announcement from the U.S. Food and Drug Administration (FDA), which flagged deficiencies in the company's New Drug Application (NDA) concerning Anaphylm, their experimental treatment for severe allergic reactions, including anaphylaxis.
The FDA's identification of these deficiencies has raised significant concerns. It is known that such issues can greatly hinder the progress of drug approvals, as they obstruct discussions about essential labeling and post-marketing requirements. Thus, with the PDUFA action date slated for January 31, 2026, the specter of an approval delay looms large over Aquestive's future.
In light of these developments, Faruqi & Faruqi is urging shareholders of Aquestive Therapeutics, especially those who have incurred significant losses, to consider their legal options vigorously. Since its establishment in 1995, Faruqi & Faruqi has successfully recovered hundreds of millions of dollars for numerous investors, making it a powerhouse in securities litigation.
Investors are encouraged to evaluate their standing in relation to Aquestive Therapeutics and can find more information about the investigation on the firm’s dedicated webpage. Those wishing to discuss their situation directly can contact senior partner Josh Wilson either by phone or through their official website, www.faruqilaw.com/AQST.
Faruqi & Faruqi operates multiple offices across major locations including New York, Pennsylvania, California, and Georgia, which allows them to serve a diverse clientele effectively. The firm's reputation is founded not only on their legal prowess but also on the emphasis they place on confidentiality and individual client attention.
The situation regarding Aquestive Therapeutics is a reminder of the volatile nature of the pharmaceutical sector, especially concerning approvals from regulatory bodies like the FDA. Stakeholders in the healthcare industry are reminded of the importance of staying informed about their investments, particularly those that hinge significantly on regulatory milestones.
As the investigation unfolds, updates will be shared via platforms like LinkedIn, X, and Facebook, allowing concerned investors to stay abreast of any new developments regarding Aquestive Therapeutics and potential claims that may arise.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.